Atlas Trials

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Clinical trial NCT03364231 · COMPLETED

Trial details

NCT number
NCT03364231
Sponsor
TG Therapeutics, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Marginal Zone LymphomaWaldenstrom MacroglobulinemiaNon Follicular Indolent Non-Hodgkin Lymphoma
Start date
2017-11-30
Primary completion
2022-02-15
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.